US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.3950

-0.0449-10.21%

Post-market: 0.40000.0050+1.27%18:47 EDT

Volume:35.77K

Turnover:14.47K

Market Cap:8.03M

PE:5.17

High:0.4100

Open:0.4099

Low:0.3903

Close:0.4399

Loading ...

Overview Company News Filings

Press Release: Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

Exciting Crypto ETF Expansion: HashDex Adds Litecoin, XRP & More to Nasdaq Fund

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

ORYZON to Provide Corporate Progress Updates at Several Events in March-April

Tempus Announces Acquisition of Deep 6 AI

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML

Nine's Domain tax bill could reach $240 million if CoStar agrees deal

Shell plc Fourth Quarter 2024 Euro and GBP Equivalent Dividend Payments

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Shell plc announces changes to the Executive Committee

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Sempra Reports 2024 Financial and Business Results

Scotiabank reports first quarter results

DMC Global Reports Fourth Quarter Financial Results

Press Release: Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Precision Drilling Announces 2024 Fourth Quarter and Year End Unaudited Financial Results

BCE reports 2024 Q4 and full-year results, announces 2025 financial targets

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NCI/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":0.395,"timestamp":1745265600000,"preClose":0.4399,"halted":0,"volume":35765,"hourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.395,"latestTime":"18:47 EDT","volume":1903,"amount":772,"timestamp":1745275632084},"delay":0,"floatShares":1726200,"shares":20320000,"eps":0.076408,"marketStatus":"Not Yet Opened","change":-0.0449,"latestTime":"04-21 16:00:00 EDT","open":0.4099,"high":0.41,"low":0.3903,"amount":14473.787921,"amplitude":0.044783,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.076408,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745308800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":0.4399,"dividendRate":0.506329,"preHourTrading":{"tag":"盘前","latestPrice":0.4,"preClose":0.4,"latestTime":"08:00 EDT","volume":2,"amount":0.8,"timestamp":1745236803068},"postHourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.395,"latestTime":"18:47 EDT","volume":1903,"amount":772,"timestamp":1745275632084},"volumeRatio":0.354077},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":1726200,"roa":"6.28%","roe":"58.31%","lyrEps":0.031396,"volumeRatio":0.354077,"shares":20320000,"dividePrice":0.2,"high":0.41,"amplitude":0.044783,"preClose":0.4399,"low":0.3903,"week52Low":0.3501,"pbRate":"1.25","psRate":"0.35","week52High":11.39,"institutionHeld":0.7857,"latestPrice":0.395,"eps":0.076408,"divideRate":0.506329,"volume":35765,"delay":0,"ttmEps":0.076408,"open":0.4099,"prevYearClose":0.66,"prevWeekClose":0.4399,"prevMonthClose":0.48,"prevQuarterClose":0.48,"fiveDayClose":0.43,"twentyDayClose":0.4159,"sixtyDayClose":0.68},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520033549","title":"Press Release: Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520033549","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520033549?lang=en_us&edition=fundamental","pubTime":"2025-03-19 18:30","pubTimestamp":1742380200,"startTime":"0","endTime":"0","summary":"-- Targeting final FDA approval of YUTREPIA after expiration of. -- Advancing pipeline of inhaled treprostinil products in clinical studies. -- Strengthened financial position by up to $100 million via amendment to. Dr. Roger Jeffs, Liquidia's Chief Executive Officer, said: \"Building on our progress this past year, Liquidia has strengthened its financial position, with up to an additional $100 million available pursuant to an amendment to its existing financing agreement with HCRx, while remaining poised for the potential approval and commercialization of YUTREPIA after the expiration on May 23, 2025 of the regulatory exclusivity that is currently preventing final approval. We continue to have our sights set on fulfilling our promise to provide physicians and patients with what we believe can be a much-needed therapeutic alternative, and potentially the prostacyclin of first choice, for patients with PAH and PH-ILD.\". Liquidia continues to progress clinical studies of L606  inhalation ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4604","NCI","BK4099","BK4202","BK4232","BK4555","TM","BK4022","BK4585","BK4007","BK4588","LQDA","03160"],"gpt_icon":0},{"id":"2520784126","title":"Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®","url":"https://stock-news.laohu8.com/highlight/detail?id=2520784126","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520784126?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA or OPDIVO can result in improved patient outcomes. - MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA and OPDIVO. - Trials supported by preclinical data showing Actimab-A can selectively target and deplete MDSCs which express CD33. - Clinical proof of concept data expected in 2025 could potentially open up a multi-billion-dollar market opportunity for Actimab-A as a combination therapy with PD-1 inhibitors in multiple solid tumors. Actimab-A is Actinium's lead radiotherapeutic that delivers Actinium-225, a potent alpha-emitter radioisotope payload that can produce lethal double strand DNA br","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-clinical-trial-120000511.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-clinical-trial-120000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989771016.USD","LU1941712264.USD","LU1169589451.USD","IE00BFTCPJ56.SGD","CR","LU1941712348.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0965509101.SGD","LU1037948541.HKD","LU1057294990.SGD","LU2324357040.USD","ATNM","PD","LU1934455194.USD","LU1934455277.USD","HMA","LU0266013472.USD","IE00B4R5TH58.HKD","LU1989772840.SGD","SG9999013999.USD","LU1116320737.USD","LU1974910355.USD","LU0965509283.SGD","BK4202","IE0002141913.USD","LU1116320901.HKD","SG9999002232.USD","MRK","LU2023250504.SGD","LU0320765646.SGD","SG9999014542.SGD","IE00B2B36J28.USD","LU1929549753.HKD","LU0289739699.SGD","NCI","SG9999015358.SGD","SG9999015341.SGD","IE0009355771.USD","LU1989772923.USD","SG9999001176.SGD","LU2023250843.SGD","LU1037948897.HKD","SGXZ57979304.SGD","LU0985320562.USD","BK4023","LU1093756325.SGD","LU1699723380.USD","LU1983299246.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2520684400","title":"Exciting Crypto ETF Expansion: HashDex Adds Litecoin, XRP & More to Nasdaq Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2520684400","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520684400?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:44","pubTimestamp":1742247863,"startTime":"0","endTime":"0","summary":"Get ready for a significant shake-up in the crypto investment landscape!HashDex, a well-known cryptocurrency asset management firm, is making waves with its latest move. They’re not just sitting still; they’re actively expanding their offerings to give investors broader access to the exciting world of digital assets. The buzz is all about their Nasdaq Crypto Index ETF , which is set to welcome a host of new cryptocurrencies into its fold. This update could be a game-changer for anyone looking to diversify their crypto portfolio through a traditional investment vehicle.Understanding the HashDex ETF and its Crypto ETF Expansion. This is a diverse selection, covering different sectors within the cryptocurrency market, from payments and smart contracts","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67d897b851a79047c48a2366/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["UNI.USD.HKCC","USJW.SI","LINK","LU2210150020.SGD","AVAX.USD.HKCC","LTC.USD.CC","LTC.USD.HKCC","QID","PSQ","UNI.USD.CC","APT.USD.CC","TSYW.SI","IE00B3QW5Z07.USD","NCIQ","BK4585","SQQQ","AVAX.USD.CC","TON.USD.HKCC","IE00BGHQF748.EUR","BK4588","BK4157","BK4519","SOL","FDN","LU2095319765.USD","IE00B64PRP62.GBP","BK4203","BK4225","BK4202","BK4550","BK4129","APT.USD.HKCC","NDAQ","QLD","MNQmain","IE00BKPKM429.USD","NCI","TON.USD.CC","USAW.SI","BK4112","SOL.USD.HKCC","TQQQ","NVIW.SI","NQmain","LU2210149790.SGD",".IXIC","LTC"],"gpt_icon":1},{"id":"2520443526","title":"Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2520443526","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520443526?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:50","pubTimestamp":1742215800,"startTime":"0","endTime":"0","summary":"- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy. - Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment. - Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial. 52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy. Actimab-A + CLAG-M produced high rates of measurable residual disease negativity  including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy. Dr. Sameem Abedin, Associate Professor of Medicine at the Medical College of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MCW","OS","ATNM","BK4192","NCI","HMA","BK4097","BK4202","BK4161","BK4139","BK4539","BK4535","CR"],"gpt_icon":0},{"id":"2519809876","title":"ORYZON to Provide Corporate Progress Updates at Several Events in March-April","url":"https://stock-news.laohu8.com/highlight/detail?id=2519809876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519809876?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:00","pubTimestamp":1741953600,"startTime":"0","endTime":"0","summary":"MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025  -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in March-April.About OryzonFounded in 2000 in Barcelona, Spain, Oryzon  is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS  and iadademstat in oncology . The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oryzon-corporate-progress-updates-several-120000379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1074936037.SGD","BK4516","LU0320765646.SGD","LU1363072403.SGD","LU2111349929.HKD","LU1720051017.SGD","BK4585","BK4534","BK4139","LU2347655156.SGD","LU0314104364.USD","IE00BZ1G4Q59.USD","BK4548","BK4581","LU0795875169.SGD","LU0267386448.USD","LU0795875086.SGD","LU1989772923.USD","LU0225283273.USD","LU1732800096.USD","BK4613","LU2028103732.USD","LU2089284900.SGD","IE00BKVL7J92.USD","BK4554","LU1989772840.SGD","ORYZF","BK4504","BK4202","PRGS","LU0912757837.SGD","LU2133065610.SGD","LU0098860793.USD","NCI","LU1548497426.USD","LU1732799900.SGD","LU0158827948.USD","LU0971096721.USD","LU0006306889.USD","LU1162221912.USD","LU0106261372.USD","BK4127","LU2023251221.USD","LU0158827781.USD","BK4116","NET","LU0106831901.USD","LU2357305700.SGD","LU2286300806.USD","BK4588"],"gpt_icon":0},{"id":"2518070831","title":"Tempus Announces Acquisition of Deep 6 AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2518070831","media":"Business Wire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518070831?lang=en_us&edition=fundamental","pubTime":"2025-03-12 05:15","pubTimestamp":1741727700,"startTime":"0","endTime":"0","summary":"Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network. CHICAGO, March 11, 2025----Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies.Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence  with speed and precision. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record  data across a broad ecosystem, which includes academic medical centers, National Cancer Institute -Designated Cancer Centers, and NCI Community Oncology Research Programs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-announces-acquisition-deep-6-211500475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BVYPNW00.USD","IE00B3PB1722.GBP","BK4613","LU1861558580.USD","BK4096","LU1861559042.SGD","LU2355687059.USD","IE00BGHQF631.EUR","IE00BVYPNV92.GBP","IE00BDGV0183.EUR","IE00B42XCP33.USD","SG9999011175.SGD","BK4543","BK4202","BK4597","EMR","BK4588","BK4585","BK4533","BK4611","BK4121","SG9999003800.SGD","TEM","NCI"],"gpt_icon":1},{"id":"2518745220","title":"Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2518745220","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518745220?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:30","pubTimestamp":1741696200,"startTime":"0","endTime":"0","summary":"Represents first ever triplet combination using targeted radiotherapy as a backbone therapy inAML with initial clinical data expected in 2H:2025. Dr. Avinash Desai, Actinium's Chief Medical Officer, commented, \"We are incredibly excited that the first Actimab-A trial initiated under our CRADA with the NCI is this triplet combination with Venetoclax and Taiho's ASTX-727. While Ven-HMA has positively impacted outcomes in AML, a significant number of patients have poor responses or relapse quickly resulting in dismal outcomes. We believe Actimab-A's potentially synergistic, and mutation agnostic mechanism of action can improve clinical outcomes for these patients by producing deeper remissions, including measurable residual disease negativity, that are more durable. Due to its mutation agnostic mechanism, Actimab-A can overcome high-risk features, such as TP53 mutations, and has demonstrated the ability to improve outcomes in these patients where Ven-HMA has had limited success. This trip","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-initiation-actimab-123000179.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-initiation-actimab-123000179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4202","HMA","ATNM","NCI","BK4161","CR"],"gpt_icon":0},{"id":"2518008200","title":"Nine's Domain tax bill could reach $240 million if CoStar agrees deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2518008200","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518008200?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:00","pubTimestamp":1741636826,"startTime":"0","endTime":"0","summary":"Media giant Nine Entertainment  faces a potential capital gains tax bill of around $240 million if property portal Domain  agrees to a $4.20 per share takeover bid by US investor CoStar, according to market sources.Nine owns 60 per cent of Domain and the tax bill on any share sale means the after-tax value of CoStar's offer to the media group's shareholders may be as little as $3.57 per share.On Monday, Domain shares changed hands for $4.41 at an unusual 5% premium to the takeover bid price, as traders and hedge funds bet on CoStar lifting its offer as it faces push back from Domain's board partly on tax issues.Sources added this deal is far less likely to fall over on a tax shock than Kohlberg Kravis Roberts'bid for part of Perpetual , where the asset manager believed it had structured the deal to minimise tax before the Australian Tax Office took a different view.The difference - or estimated capital gain - of $797.6 million equals a bill of $239.3 million when applying a 30% tax rat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/nine-s-domain-tax-bill-could-reach-240-million-if-costar-agrees-deal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/nine-s-domain-tax-bill-could-reach-240-million-if-costar-agrees-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["NCI","LU0109391861.USD","BK7503","BK4202","LU0672654240.SGD","BK7062","LU0320765059.SGD","NEC.AU","MRN.AU","BK7002","CSGP","IE0004445239.USD","BK7052","BK4588","LU2095319765.USD","BK4548","BK4585","LU0708995401.HKD","DHG.AU","LU0390134368.USD","BK4079","BK4123","LU1267930730.SGD","IE0009356076.USD","LU2210150020.SGD","LU2210149790.SGD","PPT.AU"],"gpt_icon":0},{"id":"2518415293","title":"Shell plc Fourth Quarter 2024 Euro and GBP Equivalent Dividend Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2518415293","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518415293?lang=en_us&edition=fundamental","pubTime":"2025-03-10 15:00","pubTimestamp":1741590000,"startTime":"0","endTime":"0","summary":"SHELL PLC FOURTH QUARTER 2024 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS. The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the fourth quarter 2024 interim dividend, which was announced on January 30, 2025 at US$0.358 per ordinary share.Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by February 28, 2025 will be entitled to a dividend of US$0.358, 0.3315 or 27.79p per ordinary share, respectively.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling, at","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-plc-fourth-quarter-2024-070000764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765646.SGD","LU0278409577.USD","LU0300736492.USD","NCI","BK4202","LU1162221912.USD","BK4588","LU2236285917.USD","BK4201","LU0300736062.USD","SHEL","LU0098860793.USD","BK4585"],"gpt_icon":0},{"id":"2517482850","title":"Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482850","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482850?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:30","pubTimestamp":1741350600,"startTime":"0","endTime":"0","summary":"Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall surv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038883/0/en/Plus-Therapeutics-Announces-Peer-Reviewed-Publication-in-Nature-Communications-Highlighting-Promising-Phase-1-Results-for-Rhenium-186Re-Obisbemeda-in-Glioblastoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4139","NCI","BK4135","BK4202","BK4097","LENZ","OS"],"gpt_icon":0},{"id":"2517694151","title":"Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517694151","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517694151?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264200,"startTime":"0","endTime":"0","summary":"HOUSTON, March  06, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeuti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038083/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-for-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Leptomeningeal-Metastases-in-Patients-with-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4183","CSF","LENZ","BK4139","NCI","BK4202"],"gpt_icon":0},{"id":"2516648793","title":"Shell plc announces changes to the Executive Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2516648793","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516648793?lang=en_us&edition=fundamental","pubTime":"2025-03-04 15:00","pubTimestamp":1741071600,"startTime":"0","endTime":"0","summary":"London, March 4, 2025  In line with its ongoing transformation, Shell announces further changes to its Executive Committee and leadership structure to support its strategy to deliver more value with less emissions.After more than a decade of distinguished service with Shell, Integrated Gas and Upstream Director, Zo Yujnovich, will step down effective 31 March 2025. Zo will assist with the transition, after which she will leave the Group. Cederic Cremers is appointed President, Integrated Gas, and Peter Costello is appointed President, Upstream, with both joining the Executive Committee effective 1 April 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-plc-announces-changes-executive-070000125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","SHEL","BK4202","NCI","LU0320765646.SGD","LU1162221912.USD","LU0300736492.USD","LU0300736062.USD","LU2236285917.USD","LU0098860793.USD","BK4585","BK4201","LU0278409577.USD"],"gpt_icon":1},{"id":"2516635992","title":"Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635992","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635992?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat  to other anti-CDI antibiotics in a germ-free mouse model. Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin -or metronidazole -treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity. Notable differences were observed between the microbiome of IBZ- and fidaxomicin -treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studies. Results establish IBZ differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX. Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI. IBZ has previously been granted FDA QIDP a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-announces-publication-nonclinical-vivo-130000861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","LU0128525689.USD","BK4202","MET","FDX","LU1291159041.SGD","LU0251131958.USD","LU0052756011.USD","BK4563","BK4539","LU1496350502.SGD","LU0048573561.USD","BK4585","NCI","VRE","BK4588","IDSA","BK4135","LU1571399168.USD","LU1267930227.SGD","BK4139","LU0251142724.SGD","PK","LU1989772840.SGD","BK4215","LU1989772923.USD","ECC","LU1989771016.USD","BK4162","BK4533","GAIN","BK4194","LU0742534661.SGD","MAA","ACXP","LU0310800965.SGD","BK4181","BK4131"],"gpt_icon":0},{"id":"2516812746","title":"New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2516812746","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516812746?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999600,"startTime":"0","endTime":"0","summary":"FREMONT, Calif., March 03, 2025----Personalis, Inc. , in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology. In this groundbreaking study, the authors highlight advancements in breast cancer residual disease  and recurrence detection using NeXT Personal, an ultra-sensitive personalized test designed to detect small traces of circulating tumor DNA  in the blood of cancer patients and survivors.\"We designed NeXT Personal to detect residual or recurrent cancer in its earliest stages. This study shows the clinical importance of ultra-sensitive ctDNA detection in early-stage bre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/publication-icr-royal-marsden-researchers-110000473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0345780281.USD","PSNL","BK4585","BK4017","LU0345780521.USD","NCI","RGLD","BK4202","SSI","BK4121","BK4588"],"gpt_icon":0},{"id":"2514099389","title":"Sempra Reports 2024 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099389","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099389?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:55","pubTimestamp":1740488100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Sempra  today reported full-year 2024 earnings, prepared in accordance with Generally Accepted Accounting Principles , of $2.82 billion or $4.42 per diluted share, compared to full-year 2023 GAAP earnings of $3.03 billion or $4.79 per diluted share. On an adjusted basis, the company's full-year 2024 earnings were $2.97 billion or $4.65 per diluted share, compared to $2.92 billion or $4.61 per diluted share in 2023.The company also reported fourth-quarter 2024 GAAP earnings of $665 million or $1.04 per diluted share, compared to fourth-quarter 2023 GAAP earnings of $737 million or $1.16 per diluted share. On an adjusted basis, the company's fourth-quarter 2024 earnings were $960 million or $1.50 per diluted share, compared to $719 million or $1.13 per diluted share in fourth-quarter 2023.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/sempra-reports-2024-financial-business-125500183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sempra-reports-2024-financial-business-125500183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0345780950.USD","IE000M9KFDE8.USD","BK4202","LU0314104364.USD","IE00B29SXK94.USD","LU0788109394.HKD","LU0251131958.USD","BK4208","LU0048573561.USD","LU0170899867.USD","LNG","BK4585","NCI","BK4588","SRE","LU1621768115.EUR","LU0368265418.SGD","LU0122376428.USD","LU2362540622.SGD","LU2362541273.HKD","LU0251142724.SGD","LU0345770308.USD","LU0345781412.USD","LU2362541513.USD","BK4144","LU0345770993.USD","LU2449327464.USD","LU0630314457.HKD","LU1621767737.EUR","LU1621768206.USD","LU0742534661.SGD","LU2384288077.EUR","LU1621767810.EUR","IE00B29SXL02.USD","LU0238689110.USD"],"gpt_icon":0},{"id":"2514617360","title":"Scotiabank reports first quarter results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514617360","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514617360?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:30","pubTimestamp":1740479400,"startTime":"0","endTime":"0","summary":"First Quarter 2025 Highlights on a Reported Basis . Net income of $993 million , compared to $2,199 million. Earnings per share  of $0.66, compared to $1.68. Net income of $2,362 million, compared to $2,212 million. \"Our results this quarter demonstrate the value of our diversified franchise and continued focus on deepening relationships with clients across our footprint,\" said Scott Thomson, President and CEO of Scotiabank. \"We are encouraged by the progress towards our stated medium-term financial objectives and remain focused on supporting our clients as they navigate through this challenging period of economic uncertainty.\". International Banking generated adjusted earningsof $692 million, down 7% year-over-year, reflecting solid but more normalized business banking and capital markets performance relative to the record results in the same quarter last year. Strong 6% quarter-over-quarter ear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scotiabank-reports-first-quarter-results-103000021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USA","BK4207","BK4202","NCI","BNS"],"gpt_icon":0},{"id":"2514705186","title":"DMC Global Reports Fourth Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705186","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514705186?lang=en_us&edition=fundamental","pubTime":"2025-02-25 05:01","pubTimestamp":1740430860,"startTime":"0","endTime":"0","summary":"Fourth quarter sales were $152.4 million, flat sequentially and down 12% versus Q4 2023Net income attributable to DMC was $0.3 million, while total net loss was $1.2 millionAdjusted net income attribu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/24/3031495/0/en/DMC-Global-Reports-Fourth-Quarter-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI","BOOM","BK4179"],"gpt_icon":0},{"id":"2512915111","title":"Press Release: Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2512915111","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512915111?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:31","pubTimestamp":1739881860,"startTime":"0","endTime":"0","summary":"$3.7 Million Private Placement Financing from Existing Investors. $2.0 Million Funding Advance from the Cancer Prevention and Research Institute of Texas . \"We are grateful for the enthusiasm and ongoing support from both existing investors and key funding agencies, including CPRIT, the National Institutes of Health, and the U.S. Department of Defense,\" said Marc H. Hedrick, M.D., Plus Therapeutics' President and Chief Executive Officer. \"This capital, along with expected grant allocations later in 2025, is expected to fully support the completion of two planned LM trials, strategically positioning the company for a pivotal trial in 2026.\". The gross proceeds to the Company from the private placement were approximately $3.7 million, before deducting offering expenses payable by the Company. The Company currently intends to use the net proceeds from the private placement for general corpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4604","BK4588","CSF","PSTV","03160","CNS","BK4139","BK4135","LENZ","BK4585","NCI","TM","NGS","BK4179","BK4555","BK4202"],"gpt_icon":0},{"id":"2511376375","title":"Precision Drilling Announces 2024 Fourth Quarter and Year End Unaudited Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2511376375","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511376375?lang=en_us&edition=fundamental","pubTime":"2025-02-13 07:45","pubTimestamp":1739403900,"startTime":"0","endTime":"0","summary":"CALGARY, Alberta, Feb.  12, 2025  (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/12/3025517/0/en/Precision-Drilling-Announces-2024-Fourth-Quarter-and-Year-End-Unaudited-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSU","LU2449327464.USD","NCI","CWC","LU0742534661.SGD","LU0788109394.HKD","LU0368265418.SGD","LU0251131958.USD","LU0314104364.USD","LU0345781412.USD","LU0345780950.USD","IE00B29SXK94.USD","LU0345770308.USD","LU0345770993.USD","IE00B29SXL02.USD","LU0170899867.USD","BK4092","BK4144","LU0122376428.USD","PDS","LU0251142724.SGD","LU0048573561.USD","BK4202","LNG","LU0630314457.HKD"],"gpt_icon":0},{"id":"2509221493","title":"BCE reports 2024 Q4 and full-year results, announces 2025 financial targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2509221493","media":"CNW Group","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509221493?lang=en_us&edition=fundamental","pubTime":"2025-02-06 19:30","pubTimestamp":1738841400,"startTime":"0","endTime":"0","summary":"This news release contains forward-looking statements. For a description of the related risk factors and assumptions, please see the section entitled \"Caution Regarding Forward-Looking Statements\" later in this news release.The information contained in this news release is unaudited.All non-revenue and revised revenue guidance targets for 2024 achieved. Adjusted EBITDA1 growth of 1.5% in Q4 delivered 0.9 percentage-point increase in adjusted EBITDA margin2 to 40.6% – highest Q4 margin in more than three decades. Q4 net earnings of $505 million, up 16.1%, with net earnings attributable to common shareholders of $461 million, up 20.7% or $0.51 per common share; 4.1% increase in adjusted net earnings1 of $719 million drove adjusted EPS1 of $0.79, up 3.9%. Cash flows from operating activities down 20.9% in Q4 to $1,877 million; free cash flow1 decreased to $874 million on higher interest paid and timing of working capital, including impact of Canada Post strike, and cash tax installments. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bce-reports-2024-q4-full-113000270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ESG","LU2517655374.HKD","TV","LU2362540622.SGD","BK4115","DTC","IP","CPI","LU1814569148.SGD","BK4585","BK4017","IT","BK4588","LU0154245673.USD","BK4118","BK4100","LU0107464264.USD","LU2517655028.SGD","PGP","LU2463526074.USD","CCTS","BK4202","BK4552","DC","LU2517655291.USD","DB","LU2362541513.USD","BK4566","NCI","LU0154245756.USD","BCE","BK4190","BK4136","LU2362541273.HKD","BK4134"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":110,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-04-17","current":5.733501,"percent":0.087336,"low":-615.963293,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"high":50.080918,"avg":6.908672,"sd":53.27237,"marketCap":8128000},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":28.783514,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":16256000},{"date":"2024-06-07","current":28.579978,"twenty":-81.702314,"median":24.992177,"eighty":34.642796,"marketCap":16154400},{"date":"2024-06-14","current":31.815689,"twenty":-79.845114,"median":25.185699,"eighty":33.392506,"marketCap":17983200},{"date":"2024-06-21","current":25.826264,"twenty":-75.704037,"median":25.951163,"eighty":31.815689,"marketCap":14610080},{"date":"2024-06-28","current":24.010495,"twenty":-75.181642,"median":25.826264,"eighty":31.166365,"marketCap":13573760},{"date":"2024-07-05","current":21.847045,"twenty":-74.134092,"median":24.992177,"eighty":30.05711,"marketCap":12350496},{"date":"2024-07-12","current":24.005484,"twenty":-72.824666,"median":24.22361,"eighty":29.406809,"marketCap":13573760},{"date":"2024-07-15","current":23.309684,"twenty":-72.571072,"median":24.010495,"eighty":29.29759,"marketCap":13183616},{"date":"2024-08-02","current":17.799213,"twenty":-72.317479,"median":24.00799,"eighty":29.18837,"marketCap":10054336},{"date":"2024-08-09","current":15.712059,"twenty":-71.040839,"median":23.456094,"eighty":28.858081,"marketCap":8900160},{"date":"2024-08-16","current":14.71315,"twenty":-69.000048,"median":23.177414,"eighty":28.661392,"marketCap":8331200},{"date":"2024-08-23","current":15.475212,"twenty":-65.359249,"median":22.360574,"eighty":28.479131,"marketCap":8761984},{"date":"2024-08-30","current":15.211668,"twenty":-16.796281,"median":21.73132,"eighty":28.375818,"marketCap":8611616},{"date":"2024-09-06","current":15.60865,"twenty":14.533412,"median":17.564477,"eighty":28.127716,"marketCap":8839200},{"date":"2024-09-13","current":18.316746,"twenty":14.714645,"median":17.091682,"eighty":27.226945,"marketCap":10363200},{"date":"2024-09-20","current":30.136472,"twenty":14.729124,"median":17.451967,"eighty":27.226945,"marketCap":17068800},{"date":"2024-09-27","current":18.155945,"twenty":14.756986,"median":17.799213,"eighty":26.316487,"marketCap":10304272},{"date":"2024-10-04","current":24.668714,"twenty":14.779837,"median":18.134605,"eighty":27.226945,"marketCap":14022832},{"date":"2024-10-11","current":19.411936,"twenty":14.800605,"median":18.316746,"eighty":26.316487,"marketCap":11029696},{"date":"2024-10-18","current":27.159393,"twenty":14.841085,"median":19.188638,"eighty":26.316487,"marketCap":15422880},{"date":"2024-10-25","current":22.801653,"twenty":14.96086,"median":20.067961,"eighty":27.538745,"marketCap":12954000},{"date":"2024-10-31","current":26.444278,"twenty":15.097424,"median":21.615595,"eighty":28.23974,"marketCap":15016480},{"date":"2024-11-08","current":25.398607,"twenty":15.188698,"median":21.880614,"eighty":27.72766,"marketCap":14427200},{"date":"2024-11-15","current":22.207911,"twenty":15.214052,"median":22.207911,"eighty":27.409251,"marketCap":12598400},{"date":"2024-11-22","current":20.742686,"twenty":15.227723,"median":22.212919,"eighty":27.092873,"marketCap":11765280},{"date":"2024-11-29","current":19.71984,"twenty":15.244259,"median":22.031838,"eighty":26.826792,"marketCap":11184128},{"date":"2024-12-06","current":19.342155,"twenty":15.419442,"median":21.847045,"eighty":26.825987,"marketCap":10972800},{"date":"2024-12-13","current":18.931587,"twenty":15.475212,"median":20.935809,"eighty":26.444278,"marketCap":10749280},{"date":"2024-12-20","current":16.81288,"twenty":15.549996,"median":20.067961,"eighty":26.379894,"marketCap":9550400},{"date":"2024-12-27","current":7.581302,"twenty":15.240125,"median":20.023482,"eighty":26.25308,"marketCap":10741152},{"date":"2025-01-03","current":8.618162,"twenty":15.140189,"median":19.71984,"eighty":26.21899,"marketCap":12196064},{"date":"2025-01-10","current":10.05795,"twenty":14.800605,"median":19.685908,"eighty":26.181452,"marketCap":14224000},{"date":"2025-01-17","current":8.786233,"twenty":14.714645,"median":19.468094,"eighty":26.125394,"marketCap":12415520},{"date":"2025-01-24","current":9.780279,"twenty":10.25185,"median":19.354401,"eighty":26.087984,"marketCap":13817600},{"date":"2025-01-31","current":8.55813,"twenty":9.931507,"median":18.990258,"eighty":25.926183,"marketCap":12088368},{"date":"2025-02-07","current":8.034161,"twenty":9.67709,"median":18.942456,"eighty":25.806345,"marketCap":11354816},{"date":"2025-02-14","current":7.429972,"twenty":9.170381,"median":18.736365,"eighty":25.661057,"marketCap":10499344},{"date":"2025-02-21","current":7.182682,"twenty":8.786233,"median":18.611629,"eighty":25.398607,"marketCap":10166096},{"date":"2025-02-28","current":6.088957,"twenty":8.49005,"median":18.298903,"eighty":25.263582,"marketCap":8617712},{"date":"2025-03-07","current":6.285152,"twenty":8.101774,"median":18.113266,"eighty":25.252549,"marketCap":8900160},{"date":"2025-03-14","current":5.596631,"twenty":7.768683,"median":17.68941,"eighty":25.185699,"marketCap":7924800},{"date":"2025-03-21","current":6.28575,"twenty":7.480228,"median":17.54621,"eighty":25.06182,"marketCap":8900160},{"date":"2025-03-28","current":6.3175,"twenty":7.319362,"median":17.202773,"eighty":24.992177,"marketCap":8940800},{"date":"2025-04-04","current":6.433722,"twenty":7.066391,"median":16.81288,"eighty":24.761928,"marketCap":9104010},{"date":"2025-04-11","current":7.43656,"twenty":6.901399,"median":16.523806,"eighty":24.668714,"marketCap":10546080},{"date":"2025-04-17","current":5.733501,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"marketCap":8128000}],"updateTime":1745302428294}}}